A Phase Ii Study Of Concurrent Chemoradiotherapy With Weekly Docetaxel And Cisplatin In Advanced Esophageal Cancer.

e14549 Background: The optimal treatment of advanced esophageal cancer remains a controversial subject. To improve dysphagia, chemoradiotherapy (CRT) has been considered as a useful treatment for patients (pts) with unresectable esophageal cancer. This study was conducted to evaluate the clinical outcomes and safety of concurrent CRT with weekly docetaxel and cisplatin in advanced esophageal cancer. Methods: Patients with locally advanced or metastatic esophageal squamous cell carcinoma, who have adequate organ function were eligible. During CRT, docetaxel and cisplatin were given at a dose of 20 mg/m2 and 25 mg/m2, respectively at D1, D8, D15. The cycle of this treatment was 28 days. Two cycles of chemotherapy was done during radiotherapy. Radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. Results: Up to December 2009, 31 pts were enrolled. Among them 30 pts (97%) completed the planned CRT. The median age was 61 years (range: 45- 72); male/female = 29/2; ECOG performance status...